Learn about the current medication options for managing type 2 diabetes and chronic kidney disease, including SGLT2 ...

GLP-1 receptor agonists and dual agonists, such as semaglutide and tirzepatide, have become powerful tools for managing type 2 diabetes. But, like any medication, they come with side effects. From ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of ...

Note: The U.S. Food and Drug Administration (FDA) does not approve supplements for safety or effectiveness. Talk to a healthcare professional about whether a supplement is the right fit for your ...

Use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors for the treatment of type 2 diabetes does not appear to increase the risk for urinary tract infections (UTIs) compared with two other new ...

Please provide your email address to receive an email when new articles are posted on . Use of GLP-1 drugs was linked to a 23% lower mortality risk for adults with type 2 diabetes on dialysis. The ...

SEATTLE — Use of GLP-1 receptor agonists (GLP-1s) was associated with a reduction in fragility fractures among older women with type 2 diabetes (T2D) in a retrospective analysis of data from a global ...

Type 2 diabetes is caused by insulin resistance, which often develops over time, and is more likely for certain people.